ME/CFS Science @mecfsscience.org · 27/07/20261) 🇩🇪 There's now more info about the PIONEER study which will test inebilizumab (a drug that targets B-cells), in a subgroup of ME/CFS patients. It's a randomised trial at the Charité that aims to include 38 participants. 13310
ME/CFS Science @mecfsscience.org · 27/07/20262) Inebilizumab targets the CD19 a marker on B-cells; the immune cells that produce antibodies. Compared to Rituximab (which targets CD20), inebilizumab targets a broader range of B-cell subsets, including early B cells and plasmablasts. 182
